Ticker archive · $ABOS

$ABOS Filing Signals & Market Reactions

Delayed, SEO-crawlable recaps of AI-scored catalysts for $ABOS — including observed post-filing price moves. Live streaming stays exclusive to VIP.

? All delayed signals

$ABOS

$ABOS – Acumen Pharmaceuticals Phase 2 ALTITUDE-AD Trial Misses Primary Endpoint

Acumen Pharmaceuticals, Inc.

2026-10-30 00:00:00 UTC · SEC_8K · All $ABOS

?? Negative AI Sentiment (-9.0 / 10)

Sabirnetug (ACU193) Phase 2 ALTITUDE-AD trial failed to meet primary endpoint of cognitive decline (iADRS) vs placebo at 18 months.
Failure observed across both tested doses (35 mg/kg and 50 mg/kg).
Highly negative clinical outcome for the company's lead Alzheimer's candidate.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?

$ABOS

$ABOS – Acumen Pharmaceuticals Reports Q3 2026 Results, Cash at $78.6M

Acumen Pharmaceuticals, Inc.

2026-10-26 00:00:00 UTC · SEC_8K · All $ABOS

?? Negative AI Sentiment (-1.5 / 10)

Total cash, equivalents, and marketable securities stood at $78.6M as of September 30, 2026
Topline results for Phase 2 ALTITUDE-AD study expected in November 2026
Net loss of $78.8M for the first nine months of 2026 reflects continuous clinical cash burn

Observed market reaction after signal

4h +3.28%

Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?